An observational study in Respiratory Tract Disease and Influenza, sponsored by Abt Associates. Completed at 2 sites in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by Abt Associates · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Influenza, Human with a site in Israel — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · Israel.
Among the 36 studies in Influenza, Human with a site in Israel, this one is one of 2 that started in 2016, is one of 7 observational ones, and was the 25th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →3 of the 36 studies in Influenza, Human with a site in Israel are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Israel, United States, Argentina and 36 more countries
Ages 18+
UMC Utrecht · Sites in Israel, United States, Australia and 26 more countries
Ages 28 days+
Barzilai Medical Center · Sites in Israel
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 10 · Phase 4 4
First in 2005; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,400 is above the median of 397 across 334 observational studies indexed under Influenza, Human.
Median enrollment 168 across the 29 interventional studies, 2,400 across the 7 observational. Of the 27 that completed or were terminated, 14 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 36 have an industry lead sponsor. The 10 most frequent:
Abt Associates is the lead sponsor of 6 studies on the registry; none are open to participants now.
Abt Associates has 1 study filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
2 of the studies in Influenza, Human with a site in Israel that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07767019Barzilai Medical CenterClimate Change Trends and Their Impact on the Seasonal Upper Respiratory Tract Disease Burden | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Influenza, Human with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study on the Prevention of Influenza and Other Wintertime Respiratory Viruses among Healthcare Professionals in Israel Effectiveness of Influenza Vaccine in Preventing Influenza Virus Infection, Missed Work, and Patient Exposure: A Prospective Cohort Study of Healthcare Personnel (to be called the Healthcare Personnel or HCP study throughout this Data Security Plan) is to investigate vaccine effectiveness and respiratory illness among healthcare personnel (HCP). This will help to better understand the factors that influence influenza vaccination choice, individual vaccine response, and whether or not the influenza vaccine helps to prevent influenza in HCP.
Healthcare personnel (HCP) are believed to be at increased risk of influenza infection and often work while ill, which increases the risk of secondary exposure to vulnerable patients. Vaccination of HCP against influenza is an important component of infection control in healthcare settings, but persistently low rates of vaccine uptake among HCP remains a topic of international concern and debate. Although recent reviews confirm that the seasonal influenza vaccine is moderately effective in reducing the risk of influenza illness [10], multiple gaps in knowledge remain regarding the preventive value of vaccine among HCP.
During at least two consecutive influenza seasons or years, this prospective cohort study of healthcare personnel in middle-income countries has four primary objectives: (1) Describe the frequency and impact of acute respiratory illnesses (ARI) among HCP during wintertime; (2) Estimate the effectiveness of influenza vaccine in preventing symptomatic influenza illness, missed work due to influenza illness, and hours of direct patient care provided by HCP with symptomatic influenza infections; (3) Examine the association between repeated influenza vaccination and HCP's baseline immune landscape, their response to influenza vaccines, and their subsequent protection against infection; (4) Examine if influenza vaccine modifies symptom severity and duration among HCP with breakthrough influenza infections despite vaccination.
Approximately 2,400-2,800 HCP providing direct patient care will be enrolled in a prospective cohort to be followed for at least two years (or two influenza seasons). In Israel, approximately 1,200 HCPs will be enrolled in Year 1 of the study, with an expansion to full enrollment in Year 2. Thus, the investigators anticipate a 3 year cohort study in which \~1,200 participants will contribute to years 1 and 2 of the study and the remaining sample will contribute to years 2 and 3 of the study. Information on socio-demographic characteristics, current medical conditions, medical history, medical care utilization, and influenza vaccination history will be extracted from medical and employee records with the participant's permission. Other information on socio-demographics, occupational responsibilities, health status, and knowledge and attitudes about viruses and vaccines will be collected by self-report through an enrollment survey. Collection of blood specimens will occur prior to and after influenza seasons during each study year; in addition, HCP who receive the influenza vaccine will provide an additional blood draw 21-42 days after vaccination. Active surveillance to identify acute illnesses (associated with cough, runny nose, body aches, or feverishness) will occur twice-weekly during weeks of local influenza circulation. When an acute illness is identified, participants will provide a respiratory specimen (nasal self-swab) for influenza testing and complete two brief surveys during and after resolution of their illness. For a sub-sample of consented participants, additional information on attitudes toward morbidity with influenza and respiratory illness will be collected through in-depth qualitative interviews. Additional brief surveys will be completed at the end of each season/year and at the start of the second influenza season to update information on participant health, work responsibilities, and attitudes and practices associated with vaccination and other inflection control and prevention measures.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
This study's enrollment of 2,400 is above the median of 397 across 334 observational studies indexed under Influenza, Human.
Browse Influenza, Human studies →Abt Associates is the lead sponsor of 6 studies on the registry; none are open to participants now.
Compared within Influenza, Human, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Tract Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Healthcare personnel
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
exposure to influenza vaccine
Frequency of acute respiratory illness among healthcare personnel receiving influenza vaccine
Time frame: 3 years
Proportion of work days missed associated with self-reported acute respiratory illness
Time frame: 3 years
Frequency of asymptomatic and symptomatic infections (with typical or atypical symptom manifestations) with influenza viruses (and other viruses)
Time frame: 3 years
Knowledge, attitudes, and practices (KAP) that predict vaccination hesitancy and refusal among healthcare personnel
Time frame: 3 years
Plan to share: No
Ran from Sep 2016 to primary completion in Jul 2019, 34 months.
Of 37 industry-sponsored observational studies under Influenza, Human, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 34. This study's 34 months is above that.
Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abt Associates